Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India.

Journal

Applied health economics and health policy
ISSN: 1179-1896
Titre abrégé: Appl Health Econ Health Policy
Pays: New Zealand
ID NLM: 101150314

Informations de publication

Date de publication:
10 Jan 2024
Historique:
accepted: 13 12 2023
medline: 10 1 2024
pubmed: 10 1 2024
entrez: 10 1 2024
Statut: aheadofprint

Résumé

Androgen-deprivation therapy is the mainstay of treatment for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). However, the intensification of treatment with either docetaxel or novel anti-androgens (abiraterone-acetate plus prednisone [AAP], enzalutamide, and apalutamide) is being recommended based on the improved clinical outcomes and quality of life among patients. This study aimed to determine the most cost-effective drug for treatment intensification for patients with mHSPC in India. A Markov model was developed with four health states: progression-free survival, progressive disease, best supportive care, and death. Lifetime costs and consequences were estimated for four treatment sequences: AAP-first, enzalutamide-first, apalutamide-first, and docetaxel-first. Incremental cost per quality-adjusted life-year (QALY) gained with a given treatment option was compared against the next best alternative and assessed for cost effectiveness using a willingness to pay threshold of 1 × per capita gross domestic product in India. We estimated that the total lifetime cost per patient was ₹1,367,454 (US$17,487), ₹2,168,885 (US$27,735), ₹7,678,501 (US$98,190), and ₹1,358,746 (US$17,375) in the AAP-first, enzalutamide-first, apalutamide-first, and docetaxel-first treatment sequence, respectively. The mean quality-adjusted life-years lived per patient were 4.78, 5.03, 3.22, and 2.61, respectively. The AAP-first sequence incurs an incremental cost of ₹4014 (US$51) per quality-adjusted life-year gained as compared with the docetaxel-first sequence, with a 87% probability of being cost effective at the willingness-to-pay threshold of 1 × per-capita gross domestic product of India. The use of AAP-first also incurs an incremental net monetary benefit of ₹396,491 (US$5070) as compared with the docetaxel-first treatment sequence. Nearly a 48% reduction in the price of enzalutamide is required to make it a cost-effective treatment sequence as compared with AAP-first in India. We concur with the inclusion of standard-dose AAP in India's publicly financed health insurance scheme for the intensification of treatment in mHSPC as it is the only cost-effective sequence among the various novel anti-androgens when compared with the docetaxel-first treatment sequence. Furthermore, a systematic reduction in the price of enzalutamide would further help to improve clinical outcomes among patients with mHSPC.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
Androgen-deprivation therapy is the mainstay of treatment for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). However, the intensification of treatment with either docetaxel or novel anti-androgens (abiraterone-acetate plus prednisone [AAP], enzalutamide, and apalutamide) is being recommended based on the improved clinical outcomes and quality of life among patients. This study aimed to determine the most cost-effective drug for treatment intensification for patients with mHSPC in India.
METHODS METHODS
A Markov model was developed with four health states: progression-free survival, progressive disease, best supportive care, and death. Lifetime costs and consequences were estimated for four treatment sequences: AAP-first, enzalutamide-first, apalutamide-first, and docetaxel-first. Incremental cost per quality-adjusted life-year (QALY) gained with a given treatment option was compared against the next best alternative and assessed for cost effectiveness using a willingness to pay threshold of 1 × per capita gross domestic product in India.
RESULTS RESULTS
We estimated that the total lifetime cost per patient was ₹1,367,454 (US$17,487), ₹2,168,885 (US$27,735), ₹7,678,501 (US$98,190), and ₹1,358,746 (US$17,375) in the AAP-first, enzalutamide-first, apalutamide-first, and docetaxel-first treatment sequence, respectively. The mean quality-adjusted life-years lived per patient were 4.78, 5.03, 3.22, and 2.61, respectively. The AAP-first sequence incurs an incremental cost of ₹4014 (US$51) per quality-adjusted life-year gained as compared with the docetaxel-first sequence, with a 87% probability of being cost effective at the willingness-to-pay threshold of 1 × per-capita gross domestic product of India. The use of AAP-first also incurs an incremental net monetary benefit of ₹396,491 (US$5070) as compared with the docetaxel-first treatment sequence. Nearly a 48% reduction in the price of enzalutamide is required to make it a cost-effective treatment sequence as compared with AAP-first in India.
CONCLUSIONS CONCLUSIONS
We concur with the inclusion of standard-dose AAP in India's publicly financed health insurance scheme for the intensification of treatment in mHSPC as it is the only cost-effective sequence among the various novel anti-androgens when compared with the docetaxel-first treatment sequence. Furthermore, a systematic reduction in the price of enzalutamide would further help to improve clinical outcomes among patients with mHSPC.

Identifiants

DOI: 10.1007/s40258-023-00866-w PMID: 38198103
pubmed: 38198103
doi: 10.1007/s40258-023-00866-w
pii: 10.1007/s40258-023-00866-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Department of Health Research, Government of India
ID : F.No.T.11011/02/2017-HR/3100291

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Dhillon PK, Mathur P, Nandakumar A, Fitzmaurice C, Kumar GA, Mehrotra R, et al. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Oncol. 2018;19(10):1289–306.
doi: 10.1016/S1470-2045(18)30447-9
Factsheet. National Cancer Registry Programme; 2020 (ICMR-NCDIR), Bengaluru.
Hariharan K, Padmanabha V. Demography and disease characteristics of prostate cancer in India. Indian J Urol IJU J Urol Soc India. 2016;32(2):103–8.
doi: 10.4103/0970-1591.174774
Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced prostate cancer: treatment advances and future directions. Trends Cancer. 2020;6(8):702–15.
doi: 10.1016/j.trecan.2020.04.010 pubmed: 32534790
Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19(4):395–7.
doi: 10.1038/pcan.2016.30 pubmed: 27431496
ESMO. Prostate cancer. https://www.esmo.org/guidelines/guidelines-by-topic/genitourinary-cancers/prostate-cancer [Accessed 14 Dec 2022].
Guidlines: NCG. https://tmc.gov.in/ncg/index.php/107-guidlines [Accessed 14 Dec 2022].
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.
doi: 10.1056/NEJMoa1702900 pubmed: 28578639 pmcid: 5533216
Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616–22.
doi: 10.1200/JCO.22.00193 pubmed: 35420921 pmcid: 9113211
Chi KN, Chowdhury S, Bjartell A, Chung BH, Gomes AJP de S, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294–303.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.
doi: 10.1056/NEJMoa1903307 pubmed: 31150574
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–7.
doi: 10.1200/JCO.2017.75.3657 pubmed: 29384722 pmcid: 5891129
Status of non-communicable diseases (NCDs) in India. https://pib.gov.in/pib.gov.in/Pressreleaseshare.aspx?PRID=1796435 [Accessed 10 Nov 2022].
Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2020;77(3):365–72.
doi: 10.1016/j.eururo.2019.09.004 pubmed: 31679970
Sung WWY, Choi HCW, Luk PHY, So TH. A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. Front Oncol. 2021;11: 627083.
doi: 10.3389/fonc.2021.627083 pubmed: 33718198 pmcid: 7943717
Wang L, Hong H, Alexander GC, Brawley OW, Paller CJ, Ballreich J. Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: an economic evaluation based on network meta-analysis. Value Health. 2022;25(5):796–802.
doi: 10.1016/j.jval.2021.10.016 pubmed: 35500949
Health Technology Assessment in India (HTAIn): HTAIn manual. https://htain.icmr.org.in/index.php/documents/publications/htain-manual [Accessed 21 Nov 2020].
Sharma D, Prinja S, Aggarwal AK, Rajsekar K, Bahuguna P. Development of the Indian reference case for undertaking economic evaluation for health technology assessment. Lancet Reg Health Southeast Asia. 2023;16: 100241.
doi: 10.1016/j.lansea.2023.100241 pubmed: 37694178 pmcid: 10485782
Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;11(376): e067975.
doi: 10.1136/bmj-2021-067975
Korn EL, Freidlin B. 18. Clinical trial designs in oncology. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, editors. Abeloff’s clinical oncology. 6th ed. Philadelphia: Elsevier; 2020. p. 296–307.e2. https://www.sciencedirect.com/science/article/pii/B9780323476744000189 [Accessed 1 Dec 2023].
James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022;151(3):422–34.
doi: 10.1002/ijc.34018 pubmed: 35411939 pmcid: 9321995
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700.
doi: 10.1016/S1470-2045(19)30082-8 pubmed: 30987939
Armstrong A. LBA25: final overall survival (OS) analysis from ARCHES: a phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC); 2021. https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/final-overall-survival-os-analysis-from-arches-a-phase-iii-randomized-double-blind-placebo-pbo-controlled-study-of-enzalutamide-enza-an [Accessed 30 Dec 2023].
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31.
doi: 10.1056/NEJMoa1903835 pubmed: 31157964
WebPlotDigitizer. Extract data from plots, images, and maps. https://automeris.io/WebPlotDigitizer/ [Accessed 11 Jan 2022].
Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
doi: 10.1186/1471-2288-12-9 pubmed: 22297116 pmcid: 3313891
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92.
doi: 10.1016/S1470-2045(12)70379-0 pubmed: 22995653
Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer. 2017;123(2):253–62.
doi: 10.1002/cncr.30336 pubmed: 27648814
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14(2):117–24.
doi: 10.1016/S1470-2045(12)70537-5 pubmed: 23294853
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86.
doi: 10.1200/JCO.19.00799 pubmed: 31329516 pmcid: 6839905
Registrar General and Census Commissioner of India. SRS BULLETIN 2014. https://censusindia.gov.in/vital_statistics/SRS_Bulletins/SRS%20Bulletin%20-Sepetember%202014.pdf [Accessed 8 Nov 2020].
Shore ND, Laliberté F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38(8):4520–40.
doi: 10.1007/s12325-021-01823-6 pubmed: 34282527 pmcid: 8342357
Prinja S, Dixit J, Gupta N, Mehra N, Singh A, Krishnamurthy MN, et al. Development of National Cancer Database for Cost and Quality of Life (CaDCQoL) in India: a protocol. BMJ Open. 2021;11(7): e048513.
doi: 10.1136/bmjopen-2020-048513 pubmed: 34326050 pmcid: 8323373
Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, et al. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: the Indian 5-Level Version EQ-5D value set. Value Health. 2022;25(7):1218–26.
doi: 10.1016/j.jval.2021.11.1370 pubmed: 35779943
Health Benefit Package 2.0. Official Website Ayushman Bharat Pradhan Mantri Jan Arogya Yojana. National Health Authority. https://pmjay.gov.in/node/1128 [Accessed 16 Jun 2021].
Gupta N, Prinja S, Patil V, Bahuguna P. Cost-effectiveness of temozolamide for treatment of glioblastoma multiforme in India. JCO Glob Oncol. 2021;7:108–17.
doi: 10.1200/GO.20.00288 pubmed: 33449801
Gupta N, Gupta D, Dixit J, Mehra N, Singh A, Krishnamurthy MN, et al. Cost effectiveness of ribociclib and palbociclib in the second-line treatment of hormone receptor-positive, HER2-negative metastatic breast cancer in post-menopausal Indian women. Appl Health Econ Health Policy. 2022;20:609–21.
doi: 10.1007/s40258-022-00731-2 pubmed: 35534752
Prinja S, Singh MP, Guinness L, Rajsekar K, Bhargava B. Establishing reference costs for the health benefit packages under universal health coverage in India: cost of health services in India (CHSI) protocol. BMJ Open. 2020;10(7): e035170.
doi: 10.1136/bmjopen-2019-035170 pubmed: 32690737 pmcid: 7375634
Drugs, Surgical and Sutures. http://www.rmsc.health.rajasthan.gov.in/content/raj/medical/rajasthan-medical-services-corporation-ltd-/en/Approved-Rate-Lists/DrugsRC.html# [Accessed 5 Jul 2021].
Central Government Health Scheme. CGHS rate list. https://cghs.gov.in/index1.php?lang=1&level=3&sublinkid=5948&lid=3881 [Accessed 16 Jun 2021].
US Dollar to Indian Rupee Spot exchange rates for 2022. https://www.exchangerates.org.uk/USD-INR-spot-exchange-rates-history-2022.html [Accessed 12 Nov 2022].
GDP per capita (current US$): India data. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=IN [Accessed 12 Nov 2020].
Gupta D, Jyani G, Ramachandran R, Bahuguna P, Ameel M, Dahiya BB, et al. Peritoneal dialysis–first initiative in India: a cost-effectiveness analysis. Clin Kidney J. 2021;15(1):128–35.
doi: 10.1093/ckj/sfab126 pubmed: 35035943 pmcid: 8757426
Gupta N, Nehra P, Chauhan AS, Mehra N, Singh A, Krishnamurthy MN, et al. Cost effectiveness of bevacizumab plus chemotherapy for the treatment of advanced and metastatic cervical cancer in India: a model-based economic analysis. JCO Glob Oncol. 2022;8: e2100355.
doi: 10.1200/GO.21.00355 pubmed: 35286136 pmcid: 8932481
Gupta D, Singh A, Gupta N, Mehra N, Bahuguna P, Aggarwal V, et al. Cost-effectiveness of the first line treatment options for metastatic renal cell carcinoma in India. JCO Glob Oncol. 2023;9: e2200246.
doi: 10.1200/GO.22.00246 pubmed: 36795991 pmcid: 10166401
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018;36(14):1389–95.
doi: 10.1200/JCO.2017.76.4381 pubmed: 29590007 pmcid: 5941614
Saad F, Chilelli A, Hui B, Muratov S, Ganguli A, North S, et al. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. J Med Econ. 2022;25(1):583–90.
doi: 10.1080/13696998.2022.2066850 pubmed: 35469527
Zheng K, Fong A, Chan S, So T. First-line therapy for metastatic castration-sensitive prostate cancer: a network meta-analysis. Hong Kong J Radiol. 2022;25(1):6–15.
doi: 10.12809/hkjr2217393
Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O. Comparison of systemic treatments for metastatic castration-sensitive prostate cancer. JAMA Oncol. 2021;7(3):412–20.
doi: 10.1001/jamaoncol.2020.6973 pubmed: 33443584 pmcid: 7809610
Chien C, Smith M, De Porre P. Effect of food on abiraterone pharmacokinetics: a review. Int J Pharmacokinet. 2017;2(3):183–93.
doi: 10.4155/ipk-2016-0026
NCCN. Guidelines detail. https://www.nccn.org/guidelines/guidelines-detail [Accessed 11 Jan 2023].
Patel A, Tannock IF, Srivastava P, Biswas B, Gupta VG, Batra A, et al. Low-dose abiraterone in metastatic prostate cancer: is it practice changing? Facts and facets. JCO Glob Oncol. 2020;6:382–6.
doi: 10.1200/JGO.19.00341 pubmed: 32125899
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.
doi: 10.1016/S0140-6736(15)01037-5 pubmed: 26719232 pmcid: 4800035
Kanesvaran R, Castro E, Wong A, Fizazi K, Chua MLK, Zhu Y, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open. 2022;7(4): 100518.
doi: 10.1016/j.esmoop.2022.100518 pubmed: 35797737 pmcid: 9434138
Bratt O, Carlsson S, Fransson P, Kindblom J, Stranne J, Karlsson CT. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278–84.
doi: 10.1080/21681805.2022.2093396 pubmed: 35798533
Re: Cancer survival data emphasise importance of early diagnosis; 2022. https://www.bmj.com/content/364/bmj.l408/rr-4 [Accessed 10 Nov 2022].
Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY). https://www.pib.gov.in/www.pib.gov.in/Pressreleaseshare.aspx?PRID=1738169 [Accessed 22 Jun 2022].

Auteurs

Nidhi Gupta (N)

Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India.

Dharna Gupta (D)

Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research (PGIMER), Madhya Marg, Near Gol Market, Sector 14, Chandigarh, 160014, India.

Kiran Gopal Vaska (KG)

National Health Authority, Ayushman Bharat PM-JAY, Government of India, New Delhi, India.

Shankar Prinja (S)

Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research (PGIMER), Madhya Marg, Near Gol Market, Sector 14, Chandigarh, 160014, India. shankarprinja@gmail.com.
ORCID: 0000-0001-7719-6986

Classifications MeSH